The funding -- by investors including Wellington Partners and 3i; DH Capital GmbH & Co. KG; and OH Beteiligungen GmbH & Co. KG -- is the largest private biotech financing in Germany since 2001, said immatics in a statement. “This new funding will not only enable us to pursue two parallel phase II clinical studies on our two most highly developed product candidates, but will also allow us to further expand our pipeline,” said co-founder of immatics Harpreet Singh. Immatics’s therapeutic vaccine IMA901 to treat renal cell cancer is under clinical development. Another vaccine IMA910 for the treatment of intestinal cancer is scheduled to follow later this year, added the statement. In 2004, immatics received a round of financing totalling 14 mln eur, said the company.
